BMS-986466

BMS-986466 is an orally administered small molecule inhibitor that targets the protein SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2), encoded by the PTPN11 gene. SHP2 plays a key role in cell signaling pathways that promote cancer cell growth and survival—particularly in cancers with KRAS G12C mutations. By inhibiting SHP2 activity allosterically (binding at a site distinct from the active site), BMS-986466 disrupts downstream signaling required for tumor proliferation and maintenance. The drug was developed as part of a collaboration between Bristol Myers Squibb and BridgeBio/its subsidiary Navire Pharma. It has been investigated primarily for use in combination with other targeted therapies such as adagrasib or sotorasib (KRAS G12C inhibitors) and cetuximab (an EGFR inhibitor) for advanced solid tumors harboring KRAS G12C mutations[1][3][5][6][9].

Other names

BBP 398BBP398BBP-398SHP2 inhibitor - Navire PharmaSHP-2 inhibitor - Navire PharmaSHP 2 inhibitor - Navire Pharma